Latest news with #Ac-225
Cision Canada
10 hours ago
- Business
- Cision Canada
AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
HAMILTON, ON, June 17, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie) and TerraPower Isotopes, LLC (TPI) today announced a supply agreement under which TPI will provide its high-quality Actinium-225 (Ac-225) 1 isotope to support AtomVie's contract development and manufacturing (CDMO) activities in radiopharmaceuticals, providing an added value to its clients with Ac-225-based programs. The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases. The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle. "We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie. "Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes. This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies. About AtomVie Global Radiopharma (AtomVie) AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit About TerraPower Isotopes (TPI) TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at About TerraPower TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. SOURCE AtomVie Global Radiopharma Inc.
Yahoo
4 days ago
- Business
- Yahoo
Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform
BOSTON, June 13, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio's proprietary chelator Macropa™ enabling broad access worldwide. Macropa is a proprietary, best-in-class, bifunctional chelator for Actinium-225 (Ac-225), known for its strong alpha-particle emissions and its use in targeted alpha therapy (TAT) for the treatment of cancer. Macropa can be tethered to small molecules, peptides, and large polypeptides such as proteins and antibodies to enable the development of targeted radiopharmaceuticals for alpha radiotherapy. By rapidly and quantitatively complexing Ac-225 at room temperature, Macropa's unique selectivity and stability for Ac-225 enables simple "one-pot" manufacturing and improves in vivo stability of the resulting compound. "Over the past year, we have been focused on building global scientific awareness and encouraging adoption of our chelator platform across the therapeutic radiopharmaceutical community," said Bill Cupelo, Chief Business Officer of Ratio. "We are proud to see our efforts realized through an expanding global ecosystem of collaborators who can now leverage Macropa to accelerate the development and adoption of radiopharmaceuticals worldwide. By enabling broader access to our platform, we are fostering a global community aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics." Incorporated in 1995, Macrocyclics is a CDMO specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The company maintains a broad catalog of bifunctional chelating agents that are used in R&D and clinical programs across the globe. Under the terms of the agreement, researchers from academia and industry may purchase Macropa directly from Macrocyclics, enabling rapid access in many countries including Japan, Canada, Australia and majority of Europe. "Ratio's Macropa is a superior chelator for Ac-225," said Paul Jurek, Ph.D., CEO of Macrocyclics. "The ability to label quickly at room temperature provides a critical advantage, especially when working with proteins or vectors that degrade when heated. We are excited to be the exclusive manufacturer of Macropa and plan to add multiple derivatives to our catalog and provide it under GMP conditions for innovators engaged in clinical research." Macrocyclics is an exhibitor at the 2025 SNMMI Annual Meeting, located in New Orleans, LA from June 21 to June 24. Ratio will also have representatives in attendance and will host a networking event for current and potential Macropa users. About Macrocyclics Macrocyclics, Inc., founded in 1995 with headquarters in Plano, Texas, is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company stocks a catalog of products dedicated to chelation technology including bifunctional chelators, magnetic resonance agents, and reactive intermediates. The company supports rapid advancements in the field through its GMP compliant quality system, custom small molecule synthesis capabilities, and expertise in analytical development and characterization. For more information about the company, please visit: About Ratio Therapeutics Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year. Please visit for more information and follow us on Twitter (X) and LinkedIn. For information regarding ordering Macropa, please contact Macrocyclics at info@ View original content to download multimedia: SOURCE Ratio Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9's radiopharmaceutical programs. Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by ActineerTM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories. Actineer is advancing cutting-edge technologies to secure and expand its supply chain and produce industrial-scale quantities of Ac-225 at rapid speed to meet the growing global demand. Further contract details have not been disclosed. 'This agreement strengthens our ongoing collaboration with Alpha-9 and reaffirms our mission to supply Actinium-225 to companies pioneering novel radiopharmaceuticals for high unmet need cancer indications,' said Dr. Andrew Cavey, CEO of ITM. 'We deeply value Alpha-9's continued trust in our capabilities to produce industrial-scale radioisotopes, supporting the development of breakthrough treatments that can potentially improve the lives of patients with cancer worldwide.' Ac-225 is a rare medical radioisotope used in radiopharmaceuticals to treat various cancer indications. It emits high-energy alpha particles with a short penetration range in tissue, enabling precise targeting of tumor cells. Studies with Ac-225 have shown it to cause double-stranded DNA breaks in cancer cells, leading to their destruction1. Its unique qualities along with its natural scarcity and manufacturing complexities make Ac-225 a highly sought after resource. With a comparatively short half-life of approximately ten days2, Ac-225 requires a highly sophisticated manufacturing and distribution network worldwide. 'With its global strength in providing high-quality radioisotopes including. Lutetium-177 and their growing capabilities for the production of Actinium-225, ITM is a valued partner as we progress our pipeline of clinical and discovery programs to meet the needs of cancer patients,' said Alison Fleming Ph.D., COO of Alpha-9 Oncology. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. About Actineer, Inc. is a joint venture company between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM) dedicated to advancing Ac-225 technologies, quickly securing supply, and producing industrial-scale quantities of this valuable, rare medical radioisotope for the treatment of cancer. Founded in October 2023, Actineer™ Inc. together with its strong supply chain collaborators seeks to progress Ac-225 development, production, and processing technologies. It has established short-term production capabilities that is expected to lead to significantly boosting international supplies, while working long-term towards the construction of a new Actinium Production Facility (APF) in Canada. The joint venture's mission is to fulfil the unmet global manufacturing and production needs of this coveted radioisotope with significant potential in the fight against cancer. About Alpha-9 Oncology Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. For more information, please visit ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Alpha-9 ContactCorporate CommunicationsStephen MitchenerPhone: +1 617 865 1004Email: smitchener@ 1Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. PMID: 38773983; PMCID: PMC11103494. 2Hooijman, E.L., Radchenko, V., Ling, S.W. et al. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI radiopharm. chem. 9, 9 (2024). Attachment 20252404_ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce a collaboration with the Canadian Nuclear Laboratories ("CNL"). CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining alpha-particle radiotherapy Actinium-225 ("Ac-225") with Defence's proprietary Accum® delivery technology. Targeted radiotherapies using Ac-225 have shown great promise in cancer treatment. Ac-225 emits powerful alpha particles that irreparably damage cancer cells' DNA, leading to cell death. Ac-225 is typically attached to cancer-targeting antibodies. However, many of these Ac-225-antibody complexes become trapped in cellular compartments called endosomes, preventing them from reaching the cell's nucleus where they can be most effective. Defence's Accum® technology is designed to enhance the escape of these complexes from endosomes, improving their accumulation in the nucleus. This approach could reduce the required dosage levels of Ac-225, potentially minimizing side effects while maintaining therapeutic efficacy. The Ac-225 will be produced and supplied by CNL, from its Th-229/Ac-225 generator at Chalk River Laboratories. CNL will evaluate several tumor-targeting antibodies modified with Accum® technology to transport Ac-225. Studies in rodent models will assess the biodistribution, therapeutic potency, and safety profile of these selected radiolabeled antibodies. The research aims to determine how effectively the Accum®-modified antibodies deliver Ac-225 to cancer cells and their impact on tumor growth. This collaboration marks a significant step in Defence's mission to revolutionize cancer treatment through enhanced targeted therapies. By combining CNL's expertise in Ac-225 radioisotope and R&D in Targeted Alpha Therapy with Defence's innovative delivery technology, the project seeks to overcome current limitations in radioisotope-based cancer treatments. "We believe Accum® will significantly enhance the potency of Ac-225 immunoconjugates by improving therapeutic efficacy and tumor targeting. Our technology's ability to facilitate endosomal escape and increase the presence of therapeutics in cell nuclei enhances the effectiveness of alpha-particles at their primary target. Our team is confident this innovative approach will overcome current limitations in radioisotope delivery for oncology, amplifying anti-cancer effects while reducing off-target toxicity. The synergy between Accum® and CNL's expertise will advance precision oncology, leading to more effective and safer treatments," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. As the project progresses, Defence will provide updates on the development of these Accum®-enhanced radioimmunoconjugates. With the global radiopharmaceutical market projected to reach USD 16.87 billion by 2033, Defence is well-positioned to contribute to this rapidly growing field of precision About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases. For further information:Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
